Castle Biosciences IncNASDAQ:CSTL
- LAST PRICE23.1500
- TODAY'S CHANGE (%)0.1200 (0.5211%)
- Bid / Lots22.3100/ 1
- Ask / Lots23.9300/ 1
- Open / Previous Close22.9000 / 23.0300
- Day Range
- 52 Week Range
- Volume246,802
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSTL |
|---|---|---|
| 09:32 ET | 17230 | 22.9 |
| 09:36 ET | 100 | 22.71 |
| 09:39 ET | 400 | 22.4601 |
| 09:43 ET | 100 | 22.85 |
| 09:48 ET | 600 | 22.92 |
| 09:50 ET | 649 | 23.03 |
| 09:52 ET | 200 | 23.1 |
| 09:54 ET | 964 | 23.03 |
| 09:57 ET | 200 | 23.06 |
| 10:01 ET | 200 | 22.99 |
| 10:03 ET | 225 | 22.9924 |
| 10:08 ET | 161 | 23.06 |
| 10:14 ET | 100 | 22.97 |
| 10:15 ET | 325 | 22.97 |
| 10:17 ET | 100 | 22.945 |
| 10:28 ET | 100 | 22.99 |
| 10:33 ET | 400 | 22.92 |
| 10:37 ET | 4728 | 22.97 |
| 10:42 ET | 100 | 23.04 |
| 10:46 ET | 200 | 23.045 |
| 10:51 ET | 795 | 23.04 |
| 10:53 ET | 200 | 22.985 |
| 10:57 ET | 200 | 22.945 |
| 11:00 ET | 100 | 22.945 |
| 11:02 ET | 200 | 22.93 |
| 11:06 ET | 100 | 22.975 |
| 11:08 ET | 100 | 22.965 |
| 11:18 ET | 100 | 23.01 |
| 11:20 ET | 100 | 22.975 |
| 11:22 ET | 943 | 22.935 |
| 11:29 ET | 100 | 23.035 |
| 11:33 ET | 336 | 23.08 |
| 11:40 ET | 200 | 23.08 |
| 11:44 ET | 100 | 23.105 |
| 11:45 ET | 800 | 23.19 |
| 12:00 ET | 408 | 23.1978 |
| 12:02 ET | 100 | 23.255 |
| 12:05 ET | 100 | 23.22 |
| 12:07 ET | 164 | 23.2599 |
| 12:12 ET | 200 | 23.155 |
| 12:18 ET | 418 | 23.155 |
| 12:23 ET | 1611 | 23.105 |
| 12:25 ET | 100 | 23.105 |
| 12:30 ET | 421 | 23.1011 |
| 12:32 ET | 100 | 23.15 |
| 12:34 ET | 400 | 23.1 |
| 12:36 ET | 211 | 23.125 |
| 12:38 ET | 300 | 23.125 |
| 12:39 ET | 700 | 23.12 |
| 12:41 ET | 300 | 23.12 |
| 12:43 ET | 1093 | 23.13 |
| 12:52 ET | 100 | 23.0975 |
| 12:56 ET | 100 | 23.12 |
| 12:57 ET | 400 | 23.145 |
| 01:01 ET | 200 | 23.14 |
| 01:06 ET | 200 | 23.09 |
| 01:28 ET | 900 | 23.11 |
| 01:30 ET | 100 | 23.13 |
| 01:33 ET | 100 | 23.125 |
| 01:35 ET | 100 | 23.12 |
| 01:42 ET | 800 | 23.12 |
| 01:46 ET | 100 | 23.15 |
| 01:50 ET | 100 | 23.11 |
| 02:00 ET | 600 | 23.08 |
| 02:02 ET | 100 | 23.07 |
| 02:04 ET | 100 | 23.06 |
| 02:06 ET | 100 | 23.06 |
| 02:09 ET | 512 | 23.01 |
| 02:18 ET | 1889 | 22.88 |
| 02:22 ET | 400 | 22.94 |
| 02:24 ET | 218 | 22.91 |
| 02:29 ET | 100 | 22.955 |
| 02:31 ET | 100 | 22.95 |
| 02:33 ET | 100 | 22.96 |
| 02:38 ET | 100 | 22.99 |
| 02:51 ET | 295 | 23.0365 |
| 02:54 ET | 2027 | 23.005 |
| 02:56 ET | 1760 | 23.04 |
| 03:00 ET | 100 | 23.07 |
| 03:03 ET | 300 | 23.04 |
| 03:07 ET | 1500 | 23.135 |
| 03:09 ET | 600 | 23.125 |
| 03:12 ET | 475 | 23.1112 |
| 03:14 ET | 914 | 23.15 |
| 03:16 ET | 538 | 23.16 |
| 03:18 ET | 100 | 23.18 |
| 03:20 ET | 684 | 23.175 |
| 03:21 ET | 986 | 23.17 |
| 03:23 ET | 22748 | 23.085 |
| 03:25 ET | 1200 | 23.07 |
| 03:27 ET | 236 | 23.08 |
| 03:30 ET | 100 | 23.06 |
| 03:32 ET | 3930 | 23.16 |
| 03:34 ET | 200 | 23.22 |
| 03:36 ET | 100 | 23.25 |
| 03:38 ET | 717 | 23.15 |
| 03:39 ET | 200 | 23.16 |
| 03:41 ET | 2557 | 23.112 |
| 03:43 ET | 2470 | 23.113 |
| 03:45 ET | 500 | 23.075 |
| 03:48 ET | 3710 | 23.14 |
| 03:50 ET | 600 | 23.17 |
| 03:52 ET | 2419 | 23.1 |
| 03:54 ET | 1496 | 23.145 |
| 03:56 ET | 6513 | 23.19 |
| 03:57 ET | 1800 | 23.16 |
| 03:59 ET | 8019 | 23.15 |
May 30, 2024
Castle Biosciences to Present New Data at 2024 ASCO(R) Annual Meeting Highlighting Use of DecisionDx(R)-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance, from 4:30PM ET on Thursday May 30, 2024 by Dow Jones
4:30PM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
New Publication Shows DecisionDx(R)-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis, from 4:30PM ET on Wednesday May 29, 2024 by Dow Jones
4:30PM ET on Wednesday May 29, 2024 by Dow Jones
May 15, 2024
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference, from 7:00AM ET on Wednesday May 15, 2024 by Dow Jones
7:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher(R) Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024, from 7:00AM ET on Tuesday May 14, 2024 by Dow Jones
7:00AM ET on Tuesday May 14, 2024 by Dow Jones
May 10, 2024
Castle Biosciences' IDgenetix(R) Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution", from 7:00AM ET on Friday May 10, 2024 by Dow Jones
7:00AM ET on Friday May 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Castle Biosciences Inc | 649.3M | -20.2x | --- |
Paragon 28 Inc | 589.0M | -10.3x | --- |
Surmodics Inc | 598.6M | 43.7x | --- |
Mesa Laboratories Inc | 511.0M | 598.4x | --- |
OrthoPediatrics Corp | 740.6M | -31.3x | --- |
SI-BONE Inc | 566.6M | -12.3x | --- |
Company Information
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
Contact Information
- Headquarters
- 505 S Friendswood Drive 2014 SAN MIGUEL DRFRIENDSWOOD, TX, United States 77546
- Phone
- 281-796-9032
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Daniel Bradbury
- President, Chief Executive Officer, Founder, Director
- Derek Maetzold
- Chief Financial Officer
- Frank Stokes
- Chief Operating Officer
- Kristen Oelschlager
- Chief Commercial Officer
- Tobin Juvenal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $649.3M |
|---|---|
Revenue (TTM) | $250.7M |
Shares Outstanding | 27.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-1.15 |
Book Value | $14.27 |
P/E Ratio | -20.2x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
